Post-Transplant Cyclophosphamide vs Anti-Thymocyte Globulin After Reduced-Intensity Peripheral Blood Allogeneic HSCT From Fully Matched Donors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Cancer Journal
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial
Blood Cancer J 2024 Feb 19;14(1)31, E Brissot, M Labopin, H Labussière, G Fossard, P Chevallier, T Guillaume, I Yakoub-Agha, M Srour, CE Bulabois, A Huynh, S Chantepie, AL Menard, MT Rubio, P Ceballos, R Dulery, S Furst, F Malard, D Blaise, M MohtyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.